

Contact the team

eGFR-C Study Office

[Open all sections](#)

eGFR-C Study Office
FREEPOST RRKR-JUZR-HZHG
Birmingham Clinical Trials Unit (BCTU)
School of Health & Population Sciences
College of Medical and Dental Sciences
Public Health Building
University of Birmingham
Edgbaston
Birmingham B15 2TT

Email: egfr-c@trials.bham.ac.uk (<mailto:egfr-c@trials.bham.ac.uk>)

Fax: 0121 415 9135

Study Manager

- Elizabeth Brettell - 0121 415 9130

Study Co-ordinator

- Ryan Ottridge - 0121 415 9134/25

Data Manager

- Adam Khan - 0121 415 9131

Find out more information about our other renal trials

[BCTU \(/research/activity/mds/trials/bctu/index.aspx\)](#)

The University of Birmingham Clinical Trials Unit (BCTU) is a Research Unit in the School of Medicine specialising in the design, conduct and analysis of clinical trials.

[GloMY \(/research/activity/mds/trials/bctu/trials/renal/glomy/index.aspx\)](#)

GloMY is national, multi-centre, randomised controlled open-label pilot trial of Myfortic plus short course steroids versus standard care in patients with proteinuric primary focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

[PEXIVAS \(/research/activity/mds/trials/bctu/trials/renal/pexivas/index.aspx\)](#)

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial.

[PREDNOS \(/research/activity/mds/trials/bctu/trials/renal/prednos/index.aspx\)](#)

Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial

[PREDNOS 2 \(/research/activity/mds/trials/bctu/trials/renal/prednos2/index.aspx\)](#)

Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome.

[STOP-ACEi \(/research/activity/mds/trials/bctu/trials/renal/STOPACEi/index.aspx\)](#)

STOP-ACEi is a multi-centre, randomised controlled trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced kidney disease.